Al­most a year since Hu­mi­ra biosim­i­lars launched, Ab­b­Vie still con­trols more than 97% of the US mar­ket

Ab­b­Vie isn’t los­ing its con­trol of its biggest cash cow Hu­mi­ra (adal­i­mum­ab) quite yet, de­spite the in­flux of eight adal­i­mum­ab biosim­i­lars vy­ing for mar­ket share …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER